IngredientesLa proteína de pescado se refiere a la proteína completa y de alta calidad derivada de la carne de pescado o subproductos como la piel, los huesos y los órganos. Es rica en aminoácidos esenciales, incluyendo lisina, metionina, leucina y arginina, y es fácilmente digerible, lo que la convierte en una valiosa fuente de proteína tanto para la nutrición general como para aplicaciones de nutrición clínica. La proteína de pescado se extrae comúnmente de especies marinas como el bacalao, el salmón, el atún, el abadejo y las sardinas, y se procesa en formas como hidrolizados de proteína de pescado (FPH), concentrados o aislados.
Los hidrolizados de proteína de pescado son péptidos descompuestos enzimáticamente, que ofrecen una absorción más rápida, menor alergenicidad y propiedades potencialmente bioactivas, incluyendo efectos antiinflamatorios, antioxidantes, antihipertensivos y de preservación muscular. Esto hace que la proteína de pescado sea cada vez más popular en la nutrición deportiva, el cuidado geriátrico y los alimentos médicos para condiciones como la sarcopenia (pérdida muscular relacionada con la edad), la sensibilidad digestiva y la cicatrización de heridas.
La proteína de pescado también favorece el mantenimiento de la masa muscular magra, la función inmunológica y la saciedad, lo que la convierte en un componente útil en el manejo del peso y la nutrición de alto rendimiento. Algunos suplementos combinan la proteína de pescado con colágeno marino u omega-3 para obtener beneficios más amplios, particularmente para la piel, las articulaciones y el tejido conectivo. La sostenibilidad y la pureza son esenciales en la producción, y muchos fabricantes ahora obtienen proteína de subproductos del procesamiento de pescado para reducir los residuos y el impacto ambiental.
Uso Histórico
Históricamente, el pescado como fuente de proteína ha sido parte integral de las dietas de las culturas costeras y ribereñas de todo el mundo. Aunque la proteína de pescado no se extraía ni se aislaba en la antigüedad, el valor nutricional y medicinal del pescado era ampliamente reconocido. En la Medicina Tradicional China, el pescado era recomendado para mejorar el qi (energía vital) y la sangre, particularmente en el contexto de la recuperación y la nutrición posparto. Los antiguos griegos y romanos valoraban el pescado por su papel en la construcción de la fuerza y la vitalidad, y frecuentemente lo daban a los enfermos o heridos.
El pescado seco o fermentado, rico en proteína conservada, ha sido durante mucho tiempo parte de las dietas tradicionales en Escandinavia, Japón, Corea y África Occidental. Estos alimentos servían tanto como nutrición como tónicos que se creía fortalecían el cuerpo y mejoraban la resistencia. Los caldos y guisos de pescado, elaborados con huesos y cabezas, eran remedios tradicionales para mejorar la digestión, fortalecer la inmunidad y apoyar la salud articular—precursores de los modernos suplementos de proteína marina y colágeno.
El concepto de concentrados e hidrolizados de proteína de pescado comenzó en el siglo XX, particularmente durante y después de la Segunda Guerra Mundial, cuando los científicos de alimentos exploraron nuevas formas de combatir la desnutrición proteica a nivel mundial. En las últimas décadas, el interés en las proteínas marinas ha crecido no solo por su densidad nutricional sino también por su potencial bioactivo, a medida que los investigadores descubren péptidos en la proteína de pescado que pueden ayudar a regular la presión arterial, el colesterol, la inflamación y el metabolismo.
Aunque carece del largo legado folclórico de las hierbas de origen vegetal, la proteína de pescado representa una tradición rica en nutrientes arraigada en prácticas dietéticas y curativas que ha sido elevada por la ciencia alimentaria moderna a un ingrediente funcional y terapéutico.
Condiciones de salud que bromelaina puede ayudar a apoyar.
Bromelain functions as a proteolytic digestive enzyme active across both the stomach's acidic and the small intestine's alkaline environments, aiding protein breakdown and alleviating digestive discomfort. Multiple studies suggest it helps reduce gastrointestinal inflammation and supports motility. It is used as a digestive aid for individuals with impaired protein digestion.
Bromelain, a cysteine protease mixture from pineapple (Ananas comosus), has demonstrated inhibition of allergic airway disease in murine asthma models and clinical benefit in human allergic rhinitis. A controlled trial of a Boswellia serrata and bromelain compound showed significant benefit in seasonal allergic rhinitis complicated by upper respiratory infections. Mechanistically, bromelain reduces eosinophilic airway inflammation and modulates dendritic cell function.
Bromelain is documented in PMC reviews to prevent or minimize the severity of angina pectoris via its fibrinolytic, antiplatelet, and antithrombotic properties. It may break down cholesterol plaques and exerts potent fibrinolytic activity, reducing thrombus formation relevant to ischemic cardiac conditions. Two large-scale clinical studies on heart patients reportedly showed near-complete elimination of thrombosis.
Bromelain inhibits NF-κB and COX-2 pathways, reduces oxidative stress markers, and has been shown to decrease oxidative stress-related inflammatory injury. PMC reviews and systematic reviews of enzyme-antioxidant therapy in arthritis confirm anti-oxidant activities. A systematic review of osteoarthritis concluded that bromelain exerts beneficial effects partly via its antioxidant properties.
Bromelain, a mixture of proteolytic enzymes from pineapple stem, has anti-inflammatory properties through fibrinolytic and cytokine-modulating mechanisms. It has been studied in combination and solo OA preparations, referenced in OA nutraceutical systematic reviews, and the Arthritis Foundation lists it among studied supplements for knee and hip OA.
Bromelain has demonstrated anti-inflammatory activity in animal models of allergic airway disease (AAD), attenuating airway inflammation and altering CD4+/CD8+ T lymphocyte ratios. It inhibits Th2 cytokines such as IL-4 and IL-13, which drive asthmatic inflammation. While direct large-scale human RCTs in asthma are lacking, preclinical and immunological evidence supports a scientifically plausible relationship.
Clinical studies show bromelain reduces exercise-induced muscle damage, delayed-onset muscle soreness (DOMS), and inflammatory markers (CRP, IL-6) post-exercise. A randomized double-blind trial in competitive cyclists found bromelain (1000 mg/day over six race days) reduced subjective fatigue and showed a trend toward maintaining testosterone concentrations compared to placebo. Bromelain's proteolytic and anti-inflammatory properties underpin these effects.
Bromelain is recommended as an adjuvant therapeutic approach in inflammatory, malignant, and autoimmune diseases. It modulates T cell surface adhesion molecules and TGF-β expression in rheumatoid arthritis and osteomyelofibrosis. Animal studies show efficacy in the experimental allergic encephalomyelitis (EAE) model of multiple sclerosis, and immunomodulatory actions on NK cells and lymphocytes are documented.
Bromelain, the proteolytic enzyme complex from pineapple, has documented anti-inflammatory properties and has been studied for reducing swelling and inflammation from insect stings and bites by enzymatically breaking down inflammatory mediators and venom proteins. It is referenced in complementary medicine literature for insect sting management.
Bromelain from pineapple has documented anticoagulant and fibrinolytic properties. It prolongs prothrombin time and APTT, increases fibrin cleavage, and upregulates antithrombin III and plasminogen. A 2022 PMC study confirmed bromelain inhibited the coagulation cascade and promoted fibrinolytic activity in a NAFLD model through LC-MS/MS-verified protein expression changes.
Bromelain, the proteolytic enzyme complex from pineapple, has demonstrated therapeutic benefits for bronchitis and sinusitis through mucolytic, anti-inflammatory, and immunomodulatory mechanisms. German Commission E recognizes bromelain for inflammation of the upper and lower respiratory tract. Evidence reviews document its efficacy for reducing sputum viscosity and bronchial inflammation.
Bromelain is the active constituent of the EMA-approved debridement agent NexoBrid® for deep burns. Multiple RCTs and systematic reviews demonstrate bromelain-based enzymatic debridement reduces time to complete debridement, lowers surgical excision rates, and improves spontaneous healing and cosmetic outcomes compared to standard care. A 2025 meta-analysis found faster debridement (MD -3.92; p<0.00001) and higher spontaneous healing rates with bromelain.
Bromelain, a proteolytic enzyme from pineapple, is explicitly cited for bursitis by ADAM, Healthgrades, and PainScale. It reduces inflammation and swelling. A 2004 review found it showed promise for OA treatment. The NIH notes bromelain may help arthritis pain combined with trypsin and rutin. Typical dosing: 500–2,000 mg three times daily between meals.
Bromelain, the proteolytic enzyme complex from pineapple stem, has anti-inflammatory and fibrinolytic effects relevant to nerve compression syndromes. It has been studied as part of a multi-ingredient supplement for early CTS, with statistically significant improvement in nerve function and sleep quality reported. WebMD notes clinical trial evidence in CTS for bromelain-containing combinations.
Bromelain, a proteolytic enzyme from pineapple, is used in oral anti-cellulite supplements for fibrinolytic and anti-inflammatory properties. It is intestinally absorbed without degradation and is an active ingredient in a commercial anti-cellulite supplement studied in a randomized double-blind clinical trial alongside aronia extract and quercetin.
Bromelain, a cysteine protease complex from pineapple stem, has documented anti-inflammatory activity supported by multiple human clinical trials and systematic reviews. Its primary mechanisms include inhibition of NF-κB and COX-2 signaling and downregulation of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and PGE-2. A 2023 PROSPERO-registered systematic review of seven RCTs found that bromelain supplementation reduced inflammatory markers in most studies, though effect consistency is limited by population heterogeneity and varying doses and durations.
Bromelain has documented analgesic properties in human clinical studies including inflammatory pain, urogenital inflammation, post-surgical pain, and chronic arthritis. It acts directly on pain mediators such as bradykinin, reduces plasma kininogen, and inhibits PGE2. Multiple PMC reviews and clinical trials confirm its use in chronic pain settings.
Multiple preclinical and emerging clinical studies demonstrate bromelain's potential in ulcerative colitis, including an animal model showing markedly decreased IBD development and severity, and anecdotal reports of remission in two UC patients. A 2025 randomized triple-blind placebo-controlled RCT in 70 UC patients evaluated bromelain on disease activity and quality of life over 8 weeks.
Bromelain is a cysteine protease mixture extracted from pineapple stem and fruit with well-documented protein-digesting activity. It survives gastric transit and has been used in combination enzyme products for pancreatic steatorrhea and dyspepsia. Animal studies show it stimulates pancreatic trypsin activity and beneficially modulates gut microbiota.
Bromelain, a protease enzyme from pineapple, has anti-inflammatory properties studied in allergic and inflammatory conditions including eczema. It is commonly co-administered with quercetin for eczema due to its ability to enhance quercetin bioavailability and its own independent anti-inflammatory effects on immune cell function.
Bromelain is a proteolytic enzyme complex derived from pineapple stem with anti-inflammatory and anti-edematous properties relevant to joint conditions. Studies show bromelain reduces pro-inflammatory markers (MMP-3, MMP-13, IL-6, PGE2) in synovial cells (PMC8515758). It has been used in European phytotherapy for joint inflammation and is listed in the German Commission E monograph for soft tissue swelling.
Bromelain, a fibrinolytic protease from pineapple, has been tested in multiple double-blind RCTs for vitreous floater reduction. Two Taiwanese RCTs (n=280 and n=224) found high-dose mixed-fruit-enzyme supplementation including 190 mg bromelain significantly reduced vitreous opacities over 3 months. A 2025 pilot RCT also included bromelain in a multi-ingredient floater supplement with significant clinical results.
Bromelain, a cysteine protease mixture from pineapple, inhibits allergic sensitization and modulates dendritic cell activity to reduce IgE-mediated responses. Animal studies show it reduces eosinophil infiltration, BAL lymphocytes, and OVA-specific IgE in allergic airway disease models. It is traditionally combined with quercetin to improve bioavailability and address food-related inflammatory responses.
Bromelain, a cysteine protease from pineapple stem, aids protein digestion and has been studied for its role in reducing gut permeability-related food sensitivity symptoms. Animal and in vitro research (PMC9696696) show bromelain modulates gut microbiota, increasing beneficial Akkermansia muciniphila and enhancing protein digestive capacity. Bromelain is used clinically in digestive enzyme blends to support breakdown of food proteins in sensitive individuals.
Bromelain's proteolytic and anti-inflammatory properties are supported by multiple studies suggesting benefit in gastritis. It may protect GI tissues from inflammatory damage by modulating cytokines and prostaglandins, and its dual activity in both acidic and alkaline pH environments makes it active throughout the upper GI tract. PMC reviews identify gastritis as an indication supported by clinical and study evidence.
Bromelain has significant preclinical and emerging clinical evidence in IBD, including a study showing marked reduction in IBD development in IL-10-knockout mice and clinical improvement signals in ulcerative colitis patients. It blocks TNF-α receptors, suppresses NF-κB, and reduces pro-inflammatory cytokines relevant to IBD pathophysiology. A 2025 RCT specifically assessed bromelain in UC disease activity and quality of life.
Bromelain, a proteolytic enzyme from pineapple stem, has demonstrated anti-edema and anti-inflammatory properties with clinical relevance to lymphedema. It breaks down fibrin contributing to tissue hardening and improves lymphatic and blood circulation, reducing swelling. Early clinical research (Wobenzym enzyme combination studies) and a PMC-indexed pilot study support its use in fibrotic and edematous conditions including post-mastectomy lymphedema.
Bromelain, a pineapple-derived proteolytic enzyme, has clinical evidence for treating primary and secondary lymphedema. A study in Lymphology (Michelini et al., 2019; n=52) using Bromelain combined with Rutin and Melilotus in lymphedema stages I–II showed significant reductions in limb swelling and tissue thickness. Bromelain reduces inflammation and fibrin deposition in lymphatic tissues.
Bromelain, proteolytic enzymes from pineapple stem, reduces mast cell-associated microclotting, modulates Th1/Th2 immune balance, and reduces eosinophil and mast cell tissue infiltration in allergic airway models. It is frequently combined with quercetin in MCAS protocols, where it also enhances quercetin bioavailability. Evidence supports its role in multi-modal mast cell and inflammatory cascade management.
Bromelain is a complex of proteolytic enzymes from pineapple (Ananas comosus) with documented mucolytic and anti-inflammatory action on respiratory mucosa. PMC evidence shows it has significant action in dissolving bronchial secretions and acts on sinonasal mucosa. It is used for bronchitis and sinusitis to reduce mucus via proteolytic degradation of mucus glycoproteins.
Bromelain, a cysteine protease complex from pineapple stems, has shown evidence in RCTs for reducing post-exercise muscle tenderness, swelling, and pain, and improving recovery of muscle function. German Commission E and ESCOP monographs validate its use for soft tissue inflammation reduction following trauma.
Bromelain, a protease enzyme from pineapple, has evidence from clinical studies for reducing post-exercise muscle soreness and improving muscle force recovery. Two studies with a protease supplement containing 99.9 mg bromelain showed improvements in muscle force recovery and a decrease in post-exercise muscle soreness after downhill treadmill running.
Bromelain, a proteolytic enzyme from pineapple, reduces nasal mucosal inflammation and thins mucus secretions implicated in post-nasal drip. Multiple clinical studies document faster recovery from sinusitis symptoms, including nasal discharge, compared to standard or placebo treatments. A 2014 pilot study in chronic rhinosinusitis patients showed improved total symptom scores and rhinoscopy scores. A 2023 PMC case-control study found significant reduction in rhinorrhea and nasal hyperemia when bromelain was added to standard therapy.
Bromelain is a proteolytic enzyme from pineapple approved by Germany's Commission E for post-surgical pain and healing. Multiple RCTs and a systematic meta-analysis demonstrate significant reductions in post-operative pain (SMD -0.49 to -0.52) after third molar surgery. A 200-patient Phase IV RCT confirmed improved wound healing and pain reduction after elective clean surgery.
Bromelain, a proteolytic enzyme complex from pineapple, has been included in post-COVID recovery clinical protocols for its anti-inflammatory, fibrinolytic, and mucolytic properties. An RCT (PMC8472462) tested systemic enzymes including bromelain for post-COVID fatigue, showing benefits in resolving post-viral inflammatory burden and improving fatigue outcomes.
Bromelain has documented clinical use in rheumatoid arthritis (RA) dating to early case reports, and has been recommended as an adjuvant therapeutic approach in chronic inflammatory and autoimmune diseases. It suppresses TNF-α–induced NF-κB and MAPK signaling, modulates TGF-β expression in RA patients, and reduces inflammatory cytokines in synovial fibroblasts. Multiple clinical studies and PMC reviews confirm evidence of benefit.
Bromelain, a proteolytic enzyme from pineapple, has evidence for reducing post-surgical swelling and fibrin-related scar tissue formation. It is used as an adjunct to scar treatment by breaking down fibrinous proteins and reducing inflammation that drives scarring.
Bromelain, a proteolytic enzyme from pineapple, is considered a principal proposed natural treatment for hay fever (allergic rhinitis) in authoritative integrative medicine references. It reduces nasal tissue edema, decreases mucus secretion, and exerts anti-inflammatory effects through multiple pathways relevant to seasonal allergies. EBSCO Research Starters lists it as one of the principal proposed natural treatments for seasonal allergies.
Bromelain, a proteolytic enzyme from pineapple stem, has anti-inflammatory and mucolytic properties relevant to seasonal respiratory health. Animal studies demonstrate reduced airway eosinophilic inflammation in asthma models. It is used clinically as an adjunct for nasal congestion and sinusitis and is frequently combined with quercetin in allergy protocols, also proposed to enhance quercetin bioavailability.
Bromelain, a proteolytic enzyme from pineapple, has multiple clinical trials supporting its use in sinusitis. A pilot study (n=12 chronic rhinosinusitis patients) showed improved symptom scores and quality of life with 500 FIP tablets. A trial of 116 children with acute sinusitis found faster recovery in the bromelain group (6.66 vs. 7.95 days). A Cochrane-indexed systematic review rated it as having encouraging evidence as an adjunctive treatment for acute rhinosinusitis.
Bromelain, a proteolytic enzyme from pineapple stem, is approved by the German Commission E for treatment of sinus and nasal swelling. A 2013 pilot study (PubMed PMID 24273953) found good tolerability and symptom improvement in chronic rhinosinusitis. A 2006 German study in children with acute sinusitis also reported therapeutic benefit.
Bromelain, a proteolytic enzyme from pineapple stem, has clinical and observational evidence for reducing pain, swelling, and bruising from soft tissue injuries including sprains. It is approved in Germany for traumatic musculoskeletal swelling. Double-blind studies support its anti-edematous effects in blunt injuries.
Bromelain has been evaluated in clinical studies for chronic sinusitis and upper respiratory tract infections, demonstrating immunomodulatory, mucolytic, and anti-inflammatory effects on nasal mucosa. A case-control study found that adding a bromelain-containing supplement to standard sinusitis treatment improved nasal hyperemia, rhinorrhea, and inflammatory markers (WBC, IgE, CRP). It is used clinically in Europe as part of combination products for sinusitis.
Bromelain has well-documented anti-edematous properties demonstrated in multiple clinical and preclinical studies. It degrades extracellular matrix proteins, reduces tissue fluid accumulation, inhibits bradykinin-mediated vascular permeability, and is used clinically for post-surgical and post-traumatic edema. Clinical trials in orthopedic surgery and CVI confirm significant reductions in edema.
Bromelain, a proteolytic enzyme complex from pineapple stems, reduces wound inflammation, promotes eschar removal, and has been used clinically as a topical debriding agent. RCT evidence supports its use in enzymatic debridement of burns and as an oral/topical anti-inflammatory in wound management.
Bromelain, the proteolytic enzyme from pineapple, is listed by the Arthritis Foundation among herbs with anti-inflammatory properties used for gout alongside turmeric and Devil's Claw. It inhibits COX-2, reduces bradykinin, and modulates cytokines (IL-1β, IL-6, TNF-α) central to MSU crystal-triggered gout inflammation. Clinical trials support its anti-inflammatory and analgesic activity in inflammatory joint conditions.
Bromelain (a proteolytic enzyme from pineapple) is listed among herbs and enzymes reported to be effective for dysmenorrhea and menstrual disorders in a PMC systematic review of chamomile for dysmenorrhea. Its anti-inflammatory properties via prostaglandin inhibition are relevant. Traditional and complementary medicine have used it for inflammatory gynecological pain.
Bromelain, a proteolytic enzyme from pineapple, is listed among proposed natural treatments for nosebleeds, based on the hypothesis that proteolytic enzymes may help stabilize capillaries. No clinical trials have directly evaluated bromelain for epistaxis; evidence is indirect and mechanistic.
Bromelain, a proteolytic enzyme complex from pineapple, is included in parasite cleanse protocols based on its ability to digest parasite cuticle proteins, paralleling papain's anthelmintic mechanism. Traditional tropical folk medicine uses pineapple for digestive and parasitic conditions.
Bromelain is a proteolytic enzyme complex from pineapple with antiedema effects similar to those used for varicose veins, supporting its proposed use. EBSCO Research Starters lists it as an 'other proposed natural treatment' for varicose veins, noting its antiedema properties and use in inflammation and tissue swelling. No direct clinical evidence exists for varicose veins specifically, but its mechanisms (fibrinolysis, anti-inflammation, edema reduction) align with CVI pathophysiology.
Sistemas corporales que bromelaina puede ayudar a apoyar.
Volver